E-LIB Suche - Ergebnisse für: Wong, Shekman

1

Pharmacokinetics and Macrophage Inhibitory Cytokine‐1 Pharm..:

Wong, Shekman ; Krejsa, Cecile ; Lee, Dana...
Clinical Pharmacology in Drug Development. 11 (2022) 5 - p. 640-653 , 2022

Link: https://doi.org/10.1002/..

2

A population pharmacokinetic-pharmacodynamic model of navte..:

Zhang, Lu ; Poland, Bill ; Green, Michelle..
Xenobiotica. 52 (2022) 6 - p. 555-566 , 2022

Link: https://doi.org/10.1080/..

3

Clinical pharmacodynamic/exposure characterisation of the m..:

Maitland, Michael L. ; Piha-Paul, Sarina ; Falchook, Gerald...
British Journal of Cancer. 118 (2018) 8 - p. 1042-1050 , 2018

Link: https://doi.org/10.1038/..

4

Management of Venetoclax-Posaconazole Interaction in Acute ..:

Agarwal, Suresh K. ; DiNardo, Courtney D. ; Potluri, Jalaja...
Clinical Therapeutics. 39 (2017) 2 - p. 359-367 , 2017

Link: https://doi.org/10.1016/..

5

Effect of ketoconazole, a strong CYP3A inhibitor, on the ph..:

Agarwal, Suresh K. ; Salem, Ahmed Hamed ; Danilov, Alexey V....
British Journal of Clinical Pharmacology. 83 (2017) 4 - p. 846-854 , 2017

Link: https://doi.org/10.1111/..

6

Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6..:

McDaniel, Keith F. ; Wang, Le ; Soltwedel, Todd...
Journal of Medicinal Chemistry. 60 (2017) 20 - p. 8369-8384 , 2017

Link: https://doi.org/10.1021/..

7

Impact of Venetoclax Exposure on Clinical Efficacy and Safe..:

Freise, Kevin J. ; Jones, Aksana K. ; Eckert, Doerthe...
Clinical Pharmacokinetics. 56 (2016) 5 - p. 515-523 , 2016

Link: https://doi.org/10.1007/..

8

Pharmacokinetics of Venetoclax, a Novel BCL‐2 Inhibitor, in..:

Salem, Ahmed Hamed ; Agarwal, Suresh K. ; Dunbar, Martin...
The Journal of Clinical Pharmacology. 57 (2016) 4 - p. 484-492 , 2016

Link: https://doi.org/10.1002/..

9

Venetoclax does not prolong the QT interval in patients wit..:

Freise, Kevin J. ; Dunbar, Martin ; Jones, Aksana K....
Cancer Chemotherapy and Pharmacology. 78 (2016) 4 - p. 847-853 , 2016

Link: https://doi.org/10.1007/..

10

Effect of Low‐ and High‐Fat Meals on the Pharmacokinetics o..:

Salem, Ahmed Hamed ; Agarwal, Suresh K. ; Dunbar, Martin...
The Journal of Clinical Pharmacology. 56 (2016) 11 - p. 1355-1361 , 2016

Link: https://doi.org/10.1002/..

11

Clinical Predictors of Venetoclax Pharmacokinetics in Chron..:

Jones, Aksana K. ; Freise, Kevin J. ; Agarwal, Suresh K....
The AAPS Journal. 18 (2016) 5 - p. 1192-1202 , 2016

Link: https://doi.org/10.1208/..

12

Evaluation of the Pharmacokinetic Interaction between Venet..:

Salem, Ahmed Hamed ; Hu, Beibei ; Freise, Kevin J....
Clinical Drug Investigation. 37 (2016) 3 - p. 303-309 , 2016

Link: https://doi.org/10.1007/..

13

Evaluation of Rifampin's Transporter Inhibitory and CYP3A I..:

Agarwal, Suresh K. ; Hu, Beibei ; Chien, David..
The Journal of Clinical Pharmacology. 56 (2016) 11 - p. 1335-1343 , 2016

Link: https://doi.org/10.1002/..

14

Pharmacokinetics of intravenous telavancin in healthy subje..:

Worboys, Philip D. ; Wong, Shekman L. ; Barriere, Steven L.
European Journal of Clinical Pharmacology. 71 (2015) 6 - p. 707-714 , 2015

Link: https://doi.org/10.1007/..

15

Effect of Telavancin on the Pharmacokinetics of the Cytochr..:

Wong, Shekman L ; Goldberg, Michael R ; Ballow, Charles H..
Pharmacotherapy. 30 (2010) 2 - p. 136-143 , 2010

Link: https://doi.org/10.1592/..